Abstract
Objective: The aim of this paper is to review recent developments in the treatment of anorexia nervosa (AN) and how this translates to clinical and population-based care in the Australian context.
Conclusions: Overall, there is a paucity of high-quality research into treatments for AN, albeit that a number of biological and psychological interventions show promise as avenues for further research. There are significant impediments to the provision of comprehensive longitudinal care for people with AN within Australian mental health services. Evaluation of novel strategies, such as home-based support, is required as part of enhancing options for Australians suffering with AN and their families.
DISCLOSURE
Peter Bosanac has received sponsorship from AstraZeneca for an investigator-initiated open-label study of quetiapine in anorexia nervosa.